Utang jangka cendhak marang ekuitas Lantern Pharma Inc. (LTRN)

Lantern Pharma Inc. (LTRN) relies on cloud computing, which minimizes environmental harm and limits ecological impact. The business generates revenue through high-precision AI analytics to revive ineffective drugs, enabling the company to command premium pricing. The current metric stands at 0.00. This price chart confirms that US sanctions on microchips and Taiwanese risks pose serious threats to the IT infrastructure of drug development.

For Lantern Pharma Inc. (LTRN), which is developing an AI platform for cancer therapy, the short-term debt-to-market cap chart serves as an indicator of financial autonomy during the implementation of costly scientific research. This ratio compares obligations with a maturity of up to one year against equity, where low values confirm the stability of the financing structure and minimize default risk during periods of high volatility in the biotech sector.